In compliance with the disclosure obligations set forth in Article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, and as a follow-up to the disclosure of inside information sent to the National Securities Market Commission (Comisión Nacional del Mercado de Valores) and disclosed to the market on 21 October 2025 (with official registration number 2948), Laboratorios Farmacéuticos ROVI, S.A. (hereinafter "ROVI" or the "Company") hereby announces that its subsidiary ROVI Pharma Industrial Services, S.A.U. (hereinafter "ROIS") has formally signed the definitive collaboration agreement with F. Hoffmann-La Roche Ltd. (hereinafter "Roche") for the manufacture of a new drug, currently in clinical development, belonging to Roche's metabolic and cardiovascular portfolio.

The terms of the agreement stipulate that ROIS will place a high-speed filling line at its facilities in San Sebastián de los Reyes (Madrid) available to Roche.

The estimated impact of the agreement for ROVI is a minimum increase in 2030 of between 20% and 25% in contract manufacturing business (CDMO) sales compared to sales figures for 2024.